Clinical Study

A Phase III, Open-Label, Randomized Study To Investigate The Efficacy And Safety Of Atezolizumab (Anti?Pd L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin Based Chemotherapy In Pd L1?Selected Patients With Completely Resected S

Posted Date: May 14, 2017

  • Investigator: Nagla Abdel Karim
  • Co-Investigator: Lauren Hendricks
  • Specialties: Hematology/Oncology, Oncology, Cancer, Lung Cancer, Surgical Oncology
  • Type of Study: Drug

The purpose of this study is to look at the effects, good or bad, of atezolizumab on you and your NSCLC. Atezolizumab is an experimental drug, which means that health authorities have not approved atezolizumab for the treatment of NSCLC. Atezolizumab is an antibody that affects your immune system by blocking the programmed death?ligand 1 (PD L1) pathway. The PD L1 pathway is involved in decreasing your body’s natural immune response to fight cancer. By blocking the PD-L1 pathway, atezolizumab may help your immune system stop or reverse the growth of tumors.

Criteria:

To Be Eligible, Patients Must Have Completely Resected Stage Ib-Iiia Non-Small Cell Lung Cancer

Keywords:

Go29527, Cancer, Resected Nsclc, Lung, Null

For More Information:

Uc Cancer Institute
5135847698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Enhanced Recovery Program for Colorectal Surgery Patients Reduces Costs

    A standardized protocol for managing patients for the duration of colorectaloperations not only improved clinical outcomes, but also it significantlyreduced hospital costs.